Casein kinase II subunit alpha (CSNK2A1) mRNA (CSNK2A1 mRNA)

CSNK2A1 mRNA is the messenger RNA transcript that encodes the catalytic alpha subunit of Casein Kinase 2 (CK2), a ubiquitous and constitutively active serine/threonine kinase (1.3.1, 1.3.3). CK2 is a master regulator in eukaryotic cells, phosphorylating over 300 substrates to modulate critical pathways such as the cell cycle, apoptosis, DNA repair, and signal transduction (1.3.1, 1.4.4). In the context of oncology, CSNK2A1 is frequently overexpressed, which promotes tumor cell survival and chemoresistance, making the mRNA a prime target for knockdown strategies using small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs) (1.1.1, 1.1.2). Additionally, germline mutations in the CSNK2A1 gene are the primary cause of Okur-Chung neurodevelopmental syndrome (OCNDS), a rare condition characterized by intellectual disability, developmental delays, and dysmorphic features (1.2.2, 1.3.3). While small molecule inhibitors like Silmitasertib (CX-4945) target the protein product, mRNA-directed therapies offer a specific approach to modulating CK2 levels in various disease contexts (1.1.4, 1.2.4). However, the essential nature of CK2 for normal cellular homeostasis presents a significant challenge for the therapeutic window and safety (1.2.1).

Other names

CK2 alpha mRNACKII alpha mRNACasein kinase 2 alpha 1 mRNACSNK2A1 transcriptCK2A1 mRNA

RNA interference (RNAi) or antisense-mediated knockdown of the CSNK2A1 transcript, leading to reduced synthesis of the Casein Kinase II alpha protein and subsequent inhibition of downstream signaling pathways.